Reports Q3 revenue $7.492M, consensus $2.5M. “We are really pleased with our achievements in recent months which have validated both our technology and strategy as well as significantly strengthened our position for future value creation. The impressive EVX-01 data shows our capabilities in cancer vaccines and the out-licensing of EVX-B3 confirms them in infectious disease vaccines. This is very important as we maintain a number of partnership discussions across disease areas and our AI-Immunology platform,” says Birgitte Rono, CSO and interim CEO of Evaxion.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EVAX:
- Evaxion Unveils AI-Designed Cancer Vaccine Candidate EVX-04
- Evaxion Biotech expands R&D pipeline with EVX-04
- Evaxion A/S to Announce Q3 2025 Financial Results and Business Update
- Evaxion Biotech A/S Increases Share Capital Following Warrant Exercise
- Evaxion A/S Secures $7.2 Million to Extend Cash Runway